<p>Disclosed is a therapeutic agent for urinary incontinence, which has high selectivity to an a1L-adrenergic receptor and excellent metabolic stability. 2-[(5-Chloro-3-isopropyl-2-methylphenyl)methyl]imidazoline or a pharmacologically acceptable salt thereof can be used as a therapeutic agent for urinary bladder diseases including stress urinary incontinence. The compound can also be used as an a1L-adrenergic receptor agonist. The compound can also be used as a therapeutic agent for diseases more highly associated with an a1L-adrenergic receptor compared with an a1B-adrenergic receptor.</p>
